May 2025

Join the neuroendocrine cancer community on July 26, for NETRF’s 2025 Know Your NETs Virtual Patient and Caregiver Conference—a day dedicated to hope, learning, and empowerment.

This online event offers the latest updates on treatments, cutting-edge research, and real-world strategies for living well with neuroendocrine cancer. Neuroendocrine cancer experts will discuss emerging therapies such as CAR T-cell immunotherapy, Alpha PRRT, and targeted treatments. A Tumor Board will focus on how treatment sequencing decisions are made to personalize care for patients. Know Your NETs is NETRF’s most popular patient education conference and we hope you’ll join us!  

Patient enrollment has begun at a fourth site for the world’s first CAR T-cell therapy clinical trial for neuroendocrine cancer. Winship Cancer Center at Emory University School of Medicine in Atlanta has opened the trial, under the direction of Dr. Daniel Halperin. Chimeric Therapeutics is reporting early signs of efficacy in the clinical trial. Read the latest update.

In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved belzutifan as a treatment for adult and pediatric patients (12 years and older) with metastatic or inoperable tumors.  The drug is the only oral therapy for these patients. Read more about this important new treatment option.

A new global clinical trial is evaluating an investigational drug, FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations.BRAF is a gene that makes a protein involved in cell growth. In some cancers, a mutation of this gene causes the protein to stay turned on, leading to the uncontrolled growth of cancer cells. Read more.

A new clinical trial at the University of Chicago Medicine is evaluating the combination of Lutathera PRRT and a drug used in breast cancer treatment in patients with advanced pancreatic neuroendocrine tumors (PanNETs). This phase I, open-label study aims to assess the safety and preliminary tumor response of the investigational treatment combination.The clinical trial builds upon NETRF-supported research funding to Xavier Keutgen, MD.
Read more.

Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re small and seem low-risk.A new breakthrough, collaborative study led by Christopher Heaphy, PhD, and Aatur Singhi, MD, PhD and funded in part by NETRF, may help bring clarity. Drs. Heaphy and Singhi have developed a more accessible and clinically practical test that identifies a key genetic trait in PanNETs that flags tumors with a higher risk of coming back after surgery. Read more.

Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks to cutting-edge NETRF-funded research, we're one step closer to precision medicine that tailors treatments specifically for each patient. Read more about the exciting discoveries by Dr. Jules Derks that provide a new tool to improve treatment. 

In a recent interview with CancerNetwork^®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation, spotlighted our leadership as the world’s largest non-profit funder of neuroendocrine cancer research.Dr. Greene emphasized the urgent need for increased funding and researcher engagement, outlining NETRF’s four grant categories that fuel innovative, high-impact studies. Watch the interview. 

While many neuroendocrine cancers are slow-growing and manageable as chronic conditions, some types are far more aggressive. These are known as neuroendocrine carcinomas (NECs). In the latest episode of NETWise, we take a closer look at NECs—what they are, how they’re diagnosed, and the treatment options available. Whether you're a patient, caregiver, or medical professional, this episode offers essential insights into one of the most challenging forms of neuroendocrine cancer. Listen now.

This episode of the NETRF NET Thrivership Series shines a spotlight on mental health as a vital part of the neuroendocrine cancer journey, especially during Mental Health Awareness Month. We want to shine a light on the emotional side of cancer—and remind everyone: it’s not a luxury to care for your mental health. It's a necessity.

The Utah NET Cancer Support Group warmly welcomed Jessica Thomas, LCSW on May 14. Jessica met with the group and talked about the latest in neuroendocrine cancer research, Thrivership, and tools for emotional wellness. So much knowledge, hope, and community!  If your group would like a visit from the NETRF team, contact us at info@netrf.org. 

This June, our amazing community is coming together in creative, heartfelt ways to honor loved ones and fuel progress in neuroendocrine cancer research. Join the fun — in person or virtually — and be part of something powerful:

Whether you're attending, cheering from afar, or donating in support — your involvement helps drive critical research forward.

Feeling inspired to host your own event? We’d love to help. Email us at info@netrf.org to get started.

Together, we’re making breakthroughs possible — one swing, one song, one step at a time.

There are many meaningful ways to support NETRF — whether you give monthly, make a gift through your donor-advised fund, or honor a loved one with a personal fundraiser.

Popular ways to give include:

Every gift helps accelerate research and brings hope to patients and families.

Learn more at netrf.org/donate or contact us at info@netrf.org.

Anne-Marie Green is NETRF’s new Director of Digital Communications, drawing on over twenty years of experience in publishing, higher education, and nonprofits. 

Marketing scholarly journals ranging from sociology to neuroscience at Wiley gave her a deep understanding of researchers' needs and objectives. After several years working in publishing, she took on a broader corporate communications role, managing an enterprise-wide website that provided informative and engaging content for target audiences. 

She led digital communications strategy for the advancement office at Brandeis University and OpenBiome, a biotech nonprofit. She holds a Bachelor's Degree in International Culture and Economy from Bentley University. 

Anne-Marie values the opportunity to play a role in advancing neuroendocrine cancer research and supporting the patient community. 

NET Research Foundation
100 Hancock Street,
Third floor
Quincy, MA 02171
(617) 946-1780 info@netrf.org

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancer. NETRF is the largest global funder of neuroendocrine research and a preeminent resource for expert patient education and support.



NETRF is a 501(c)(3) organization. All donations are tax-deductible to the extent allowed by law.